Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
3.330
+0.090 (2.78%)
At close: May 19, 2026, 4:00 PM EDT
3.390
+0.060 (1.80%)
After-hours: May 19, 2026, 7:38 PM EDT
Larimar Therapeutics Employees
Larimar Therapeutics had 71 employees as of December 31, 2025. The number of employees increased by 6 or 9.23% compared to the previous year.
Employees
71
Change (1Y)
6
Growth (1Y)
9.23%
Revenue / Employee
n/a
Profits / Employee
-$2,338,099
Market Cap
347.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 71 | 6 | 9.23% |
| Dec 31, 2024 | 65 | 23 | 54.76% |
| Dec 31, 2023 | 42 | 16 | 61.54% |
| Dec 31, 2022 | 26 | -5 | -16.13% |
| Dec 31, 2021 | 31 | 3 | 10.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| C4 Therapeutics | 104 |
| Neumora Therapeutics | 96 |
| OmniAb | 89 |
| Rezolute | 68 |
| Atea Pharmaceuticals | 55 |
| X4 Pharmaceuticals | 45 |
LRMR News
- 1 day ago - Larimar Therapeutics price target lowered to $12 from $13 at Wedbush - TheFly
- 4 days ago - Larimar Therapeutics price target lowered to $12 from $13 at Wedbush - TheFly
- 5 days ago - Larimar Therapeutics reports Q1 EPS (31c), consensus (57c) - TheFly
- 5 days ago - Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update - GlobeNewsWire
- 5 days ago - Larimar Therapeutics Earnings release: Q1 2026 - Filings
- 5 days ago - Larimar Therapeutics Quarterly report: Q1 2026 - Filings
- 5 days ago - Larimar Therapeutics Slides: Investor presentation - Filings
- 19 days ago - Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia - GlobeNewsWire